Topical treatment of psoriasis in difficult to treat areas: Genital, folds and palmoplantar

Dr. Steven Feldman
Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands


• A self-administered questionnaire was sent to all 5300 members of the Dutch Psoriasis Society. A response rate of 37% was achieved.

• Almost 46% of the responding patients with psoriasis, that is 16.5% of all potential responders (n = 5300), report genital involvement at some time during the course of their disease.

• The genitalia may become affected at any age.
Mild topical corticosteroids
Calcineurin inhibitors topically
Calcitriol plus mild topical corticosteroid
Impact of ixekizumab treatment on skin-related sexual difficulties in moderate-to-severe psoriasis patients: 12 week results from the Phase 3 trials UNCOVER-2 and UNCOVER-3

Lyn Guenther\textsuperscript{1,2}, Howard Sofen\textsuperscript{3}, Jennifer Cather\textsuperscript{4}, Yves Poulin\textsuperscript{5}, Mark Lebwohl\textsuperscript{6}, Alison Potts Bleakman\textsuperscript{7}, Baojin Zhu\textsuperscript{7}, Enkeleida Nikai\textsuperscript{8}, Peter van de Kerhof\textsuperscript{9}

\textsuperscript{1}Department of Medicine, Division of Dermatology, University of Western Ontario, London, ON, Canada; \textsuperscript{2}Guenther Dermatology Research Centre, London, ON, Canada; \textsuperscript{3}Department of Medicine/Dermatology, UCLA School of Medicine, Los Angeles, CA, USA; \textsuperscript{4}Modern Research Associates, Dallas, TX, USA; \textsuperscript{5}Centre Dermatologique du Québec Métropolitain and Université Laval, Quebec, Canada; \textsuperscript{6}Icahn School of Medicine at Mount Sinai, New York, NY; \textsuperscript{7}Eli Lilly and Company, Indianapolis, IN, USA; \textsuperscript{8}Eli Lilly Benelux, Brussels, Belgium; \textsuperscript{9}Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Impact of ixekizumab treatment on skin-related sexual difficulties in moderate-to-severe psoriasis patients: 12 weeks results from the Phase 3 trials UNCOVER-2 and UNCOVER-3

• A similar pattern of improvement in skin-related sexual difficulties was observed in males and females (data not shown).

• In all groups, patients with complete resolution of psoriasis (PASI 100) were more likely to have no skin-related sexual difficulties at Week 12 (p=.01 and p<.001 vs. PASI<90 for UNCOVER-2 and UNCOVER-3, respectively)

Early Onset Improvement

<table>
<thead>
<tr>
<th></th>
<th>UNCOVER-2</th>
<th>UNCOVER-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBO</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>IXEQ4W</td>
<td>49</td>
<td>54</td>
</tr>
<tr>
<td>IXEQ2W</td>
<td>24</td>
<td>36</td>
</tr>
<tr>
<td>ETN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sustained Improvement

<table>
<thead>
<tr>
<th></th>
<th>UNCOVER-2</th>
<th>UNCOVER-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBO</td>
<td>68</td>
<td>80</td>
</tr>
<tr>
<td>IXEQ4W</td>
<td>51</td>
<td>67</td>
</tr>
<tr>
<td>IXEQ2W</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>ETN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Conclusions

- Ixekizumab improved skin-related sexual difficulties more than etanercept or placebo
- The improvement of skin-related sexual difficulties is rapid, with ~50% of patients reported improvement in skin-related sexual difficulties as early as week 2
  - The percentage of patients reporting improvement in skin-related sexual difficulties or impaired sexual function continued to increase through Week 12
- There was similar improvement in males and females
- Patients with complete resolution of psoriasis were more likely to have no skin-related sexual difficulties
Tacrolimus ointment is effective for facial and intertriginous psoriasis

Mark Lebwohl, Amy Krupnick Freeman, M. Shane Chapman, Steven R. Feldman, Jennifer E. Hartle. 2004;51: 723-730

- To determine the efficacy and tolerability of 0.1% tacrolimus ointment for the treatment of facial or intertriginous psoriasis

- As early as day 8, more patients ($P = .004$) had cleared or achieved excellent improvement in the 0.1% tacrolimus ointment group compared to the vehicle group (24.8% vs 5.8%). At the end of the 8-week treatment period 65.2% of the tacrolimus ointment group and 31.5% of the vehicle were clear or almost clear ($P < .0001$) based on a Static Severity Score. Adverse events were similar in the 0.1% tacrolimus ointment and vehicle groups.
Body Folds

• Penetration is good
• Topical corticosteroids
  o Risk of side effects
• Topical calcineurin inhibitors
• Topical vitamin D analogues
Palmoplantar Psoriasis

- Studies available on topical steroids, vitamin D-related agents, tazarotene, tar, phototherapy
- Topical therapies poor
- UVB photo therapy Excimer laser: Moderate effect
- PUVA or Re PUVA reasonable effect
- Methotrexate, cyclosporine, acitretine/ morphology: moderate effect
- Anti-TNF: moderate effect
- Ixekizumab and secukinumab are effective